BACKGROUND Renal transplant recipients have a significantly reduced life expectancy, largely due to premature cardiovascular disease. The aim of the current analysis was to investigate the importance of time of initiation of therapy after transplantation, on the benefits of statin therapy. METHODS 2102 renal transplant recipients with total cholesterol levels of 4.0-9.0 mmol/l were randomly a...

BACKGROUND CYP2C9*3 allele has been reported to correlate with increased plasma concentration of fluvastatin active form in healthy volunteers. We analyzed the correlation between the CYP2C9 genotype and cholesterol-lowering effect of fluvastatin in human hypercholesterolemic patients. MATERIAL/METHODS The study was prospective, without any interventions to standard procedures of hypolipidemi...

OBJECTIVES Recent reports demonstrated in vitro the efficacy of fluvastatin in inhibiting hepatitis C virus (HCV) replication and a synergistic effect in association with interferon-alpha (IFN-alpha). In vivo the inhibition of HCV replication by statins has not been demonstrated. We evaluated in this open-label, randomized controlled study the efficacy of fluvastatin as adjuvant to pegylated-(P...

Treatment of dyslipidemia patients with lipid-lowering drugs leads to a significant reduction in low-density lipoproteins (LDL) level and a low to moderate level of increase in high-density lipoprotein (HDL) cholesterol in plasma. However, a possible role of these drugs in altering morphology and distribution of cholesterol particles is poorly understood. Here, we describe the in vitro evaluati...

Statins are widely used to lower plasma concentrations of lipids, e.g. cholesterol. One of the main effects of statin treatment is inhibition of hydroxymethyl glutaryl-coenzyme A reductase. The role of fluvastatin, a frequently used statin, was examined in potential modulation of tyrosinase (key enzyme of melanogenesis) synthesis. Levels of tyrosinase mRNA induced by UVB irradiation of B16F10 m...

BACKGROUND In the LIPS (Lescol Intervention Prevention Study), fluvastatin 80 mg/day reduced the risk of major adverse cardiac events (MACE) by 22% versus placebo (p = 0.01) following successful first percutaneous coronary intervention (PCI) in patients with stable or unstable angina or silent ischemia. The cost-effectiveness of such therapy is unknown. OBJECTIVE To evaluate the cost-effectiv...

objective: to review the potential role and specific impact of statin drugs in women with pcos. the evidence for this use of statins in pcos is limited and still under further investigation. materials and methods: a search was conducted using pubmed, dynamed and pubmedhealth databases through october 16, 2016 using the terms polycystic ovary syndrome, pcos, hydroxymethylglutaryl-coa reductase i...

Fluvastatin, which is a synthetic 3-hydroxy-3-methylglutaryl coenzyme (HMG-CoA) reductase inhibitor, its metabolites (M2, M3 and M4) and trolox all inhibited the decrease of apolipoprotein B-100 (apoB) and alpha-tocopherol in a radical reaction of human plasma initiated by Cu2+. The concentrations of fluvastatin, M2, M3, M4 and trolox for 50% inhibition (IC50) of apoB fragmentation were 405, 8....

Inhibit Platelet Aggregation To the Editor: Lau et al1 recently reported that coadministration of CYP3A4metabolized statins (atorvastatin, simvastatin, and lovastatin) but not pravastatin (fluvastatin and rosuvastatin) inhibited the “antiplatelet activity of clopidogrel in a dose-dependent manner,” using an in vitro point-of-care MICROS cell counter (ABX Diagnostics) and the Plateletworks test ...